New breast cancer study: Results of the TARGIT-A clinical trial

[News]

A new clinical trial for breast cancer, published in The Lancet, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM® at time of lumpectomy is non-inferior to traditional external beam radiation (EBRT) delivered over three to six weeks after breast conserving surgery, for a select group of patients.

More... (http://www.medicalnewstoday.com/releases/269575.php)